ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Given this information, it is unlikely that durable responses can be achieved in most HNSCC patients using any single “magic bullet” therapy, as is the case for chronic myeloid leukemia patients receiving BCR-ABL inhibitors [127].